Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A wall sign showing 'MRC Population Health Research Unit'

Today, a new university unit, the Medical Research Council Population Health Research Unit  at the University of Oxford (MRC PHRU), was created within the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU).  This new Unit represents a continuation of the investment by the MRC and the University that has led, over the past 20 years, to a wide range of large observational studies and randomized trials that have had a major impact on international health.

The new Unit is directed by Professor Colin Baigent, who commented: “It is a great honour to lead the MRC Population Health Research Unit. This new collaboration between the MRC and the University of Oxford will enable us to develop the next generation of studies which, through their unusually large scale, will facilitate a better understanding of disease and allow the efficient development of safe and effective drug treatments.”

Latest news

The body ‘remembers’ inflammation, potentially increasing the risk of age-related disease later in life

Study finds blood stem cells retain ‘inflammatory memory’, shaping ageing, recovery, and disease risk, offering new insight into long‑term health.

Open-source toolkit enables discovery research within trusted research environments

Phenofhy, a new open‑source tool for streamlined phenotypic data processing and exploratory TRE work, has now launched to support biomedical discovery.

Opioid addiction linked to increased risk of dementia

Major study finds opioid addiction raises dementia risk by 56% compared with non‑users.